

Chapter 20

Haemodialysis and Peritoneal Dialysis

Patricia Piaskowski

Key Points

- Dialysis patients are at high risk of infection because of underlying illness and numerous environmental and procedural factors.
- Establishing a comprehensive infection prevention and control program for dialysis settings will reduce the infection risks for both patients and healthcare providers.
- Patient education is essential to prevent infections associated with dialysis.

Background

Healthy kidneys clean the blood and remove bodily fluids by producing urine. Dialysis can remove metabolic toxins and fluids when the kidneys fail due to disease or damage. Patients who require dialysis have an increased risk of infection due to prolonged vascular access or methods used for dialysis, immunosuppression from end stage renal disease (ESRD), or co-morbid conditions such as diabetes.

There are two types of dialysis: peritoneal dialysis (PD) and haemodialysis (HD). PD involves instillation of dialysis fluids into the peritoneal space via a surgically inserted catheter. HD utilizes a dialysis machine and a dialyser to clean the blood.

Potential adverse events for PD include peritonitis (due to contamination at time of exchange or infection of the exit site), loss of access site, and death.¹⁻³ For HD, adverse events include bacteraemia, sepsis, and loss of vascular access.^{1-2,4} Another contributing factor for infection is failure to use aseptic technique during treatment. Infection prevention and control (IPC) measures (i.e., hand hygiene, screening, surveillance, environmental cleaning, aseptic technique, Standard Precautions, and, where necessary, transmission-based precautions) are essential for preventing infections and transmission of microorganisms from patient to patient.

Transmission of infection can take place through contact with blood or body fluids, contaminated equipment, or surfaces. Blood contamination of environmental surfaces and equipment can take place during dialysis procedures. This blood contamination can then serve as a potential source of infection. Patients who are infected or colonised with microorganisms can also serve as sources for infection transmission. Staff may inadvertently spread infections from patient to patient via direct or indirect contact with contaminated surfaces/equipment or infected/colonised patients. Failure of staff to perform hand hygiene, use Standard Precautions or, when required, transmission-based precautions, such as contact or droplet, places patients at risk of infection.

Definitions

Central catheter: Central venous catheters are only intended for short term access use for HD in an emergency, while awaiting a fistula to heal, or in preparation for a graft. It carries the highest risk of infection.⁵ Standard central catheter care procedures must be followed to reduce the risk of infection.

Dialysate: A balanced electrolyte solution which is introduced on one side of the semi-permeable dialyser membrane (opposite to the patient's blood) to exchange solutes with blood during haemodialysis.⁷

Dialysis water: Purified water that is used to mix the dialysate or to disinfect, rinse, or reprocess the dialyser.⁸

Dialyser: A part of the HD machine; it has two sections separated by a membrane. The patient's blood flows through one side and the dialysate flows through the other side. (See Figure 20.1)

Endotoxin: Endotoxins are substances usually associated with Gram negative bacteria such as *Escherichia coli*, *Salmonella*, *Shigella* and *Pseudomonas*.

Endotoxin concentration: It is measured in endotoxin units per millilitre (EU/ml), while the total viable microbial load is expressed as colony forming units per ml (CFU/ml).

Fistula: A connection that is surgically created between an artery and vein (usually in the arm). It is accessed via a needle for HD. It has the lowest risk of infection.⁵

HBsAg: Hepatitis B surface antigen. All patients who are positive for HBsAg are infectious and may transmit Hepatitis B.⁵

Haemodialysis: HD utilises a dialysis machine and a special filter (dialyser) to clean the blood. The patient's blood enters the machine from the access point on the patient (e.g., a fistula, vascular graft, or a central line), is filtered, and then returned to the patient. Blood and dialysis fluids do not mix; the blood passes over a semi-permeable membrane which allows some molecules to pass through. This procedure can take up to 3-6

hours and usually takes place three times a week. It is typically carried out in an inpatient or outpatient HD area by trained staff. (See Figure 20.2)




Figure 20.1. Dialyser

[Image courtesy of National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, USA]




Figure 20.2. Haemodialysis

[Image courtesy of National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, USA]

Peritoneal dialysis: PD involves dialysis fluid instilled via a surgically inserted PD catheter into the peritoneal space of the abdomen. Most catheters are made from silicone. The fluid is removed, taking with it any toxins. Most common types of PD include chronic ambulatory PD, continuous cyclical PD, and chronic intermittent PD.⁷ (See Figure 20.3)

Reverse osmosis (RO): A process used to purify dialysis water by removing dissolved inorganic solutes as well as bacteria and their endotoxins.

Vascular graft: A synthetic tube which is surgically placed between an artery and vein (usually in the arm). This graft is accessed via a needle for HD. It carries an intermediate risk of infection.⁵




Figure 20.3. Peritoneal Dialysis

[Image courtesy of National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, USA]

Diagnosis

Diagnosis of infections related to HD or PD includes detection of the following signs and symptoms:

- Systemic infection: Fever, elevated white blood count (WBC), chills or rigors, and/or positive blood cultures.
- Peritonitis: abdominal pain, fever, elevated WBC, chills, or rigors. Culture specimens of exit site drainage and peritoneal fluid should be taken.
- Access site infections: redness or exudate at access site (vascular graft or PD catheter), nausea, vomiting, fatigue, and cloudy effluent.¹ Exudate should be cultured.

Infection-associated Risks

Hepatitis B

Hepatitis B virus (HBV) is transmitted through percutaneous or permucosal exposure to the blood of infected patients (HBsAg-positive or hepatitis B e antigen positive). Blood or body fluids from these positive patients can contaminate the environment which, even when not visibly soiled, can result in transmission of HBV.⁵

HBV remains viable at room temperature for at least seven days;⁵ it has been detected on clamps, scissors, and external surfaces and parts of dialysis machines. HBV can be transmitted to patients or staff on

gloves or unwashed hands of care providers who touch contaminated surfaces or equipment.⁵

Hepatitis B vaccine for patients is an essential component of IPC measures.⁵ Although there is currently a low incidence of HBV infection in many HD patient populations, outbreaks do occur, usually because of failure to use recommended IPC measures.

Hepatitis C

Hepatitis C virus (HCV) is transmitted primarily by percutaneous exposure to infected blood. Factors that increase the likelihood of HCV infection in HD patients include a history of blood transfusions, volume of blood transfused, and years on HD. Like HBV, HCV transmission is often related to inadequate IPC practices.

Outbreaks of HCV have been associated with patients who received their HD treatment immediately after an infected patient. Transmission of HCV has been associated with shared equipment and supplies that were not disinfected between patients, use of common medication carts, shared multi-dose medication vials, contaminated HD machines and related equipment (priming buckets), and blood spills which were not cleaned.⁴⁻⁵

Acquired immune deficiency syndrome

Human immunodeficiency virus (HIV) is transmitted by blood or blood-containing body fluids. There have been very few reports of HIV transmission in dialysis; these resulted from inadequate disinfection of equipment, including access needles.⁴⁻⁵

Bacterial disease

Dialysis patients are at increased risk of infection and colonisation with multi-drug resistant organisms (MDRO), such as methicillin-resistant *Staphylococcus aureus* (MRSA) and vancomycin-resistant enterococci (VRE). This is a result of frequent contact with health care facilities, frequent use of antibiotics, and use of invasive devices. VRE infection or colonisation has increased in some HD units. Vancomycin use is high in dialysis populations, contributing to this increase in resistance. This reduces the choice of antibiotics for treating enterococcal infections.¹⁰

Outbreaks of MRSA have occurred in some dialysis units where colonised/infected patients served as a source for transmission. In addition there have been reports of vancomycin resistant *S. aureus* (VRSA) among HD patients.⁵

Multidrug-resistant Gram-negative infections in dialysis patients including *Pseudomonas aeruginosa*, *Stenotrophomonas maltophilia*, and *Acinetobacter spp.* have occurred. Some of these infections are resistant to all current antibiotics.⁷

Dialysis patients are at risk of access site infections, bacteraemia, as well as central line-associated blood stream infections. There are also non-access related bacterial infections in dialysis patients, such as osteomyelitis, cellulitis, and chronic ulcers.

Fungi

Dialysis patients are susceptible to fungal infections caused by microorganisms such as *Aspergillus spp.* Strict adherence to IPC precautions for construction and renovation activities is important. Prompt wiping up of water or other spills prevents mould contamination of the environment with subsequent fungal infections in susceptible populations such as dialysis patients.¹ In addition; there is a risk of *Candida* bacteraemia or peritonitis with the patient's skin as a source. Dialysis patients treated with certain drugs (e.g., deferoxamine) are also at increased risk for mucormycosis.

Mycobacteria

There have been reports of mycobacterial infections in dialysis patients from contaminated water used for dialysis.¹ Patients with ESRD are at high-risk for progression from latent tuberculosis (TB) infection to active TB disease. The frequent hospitalisation of dialysis patients increases the risk of transmission of TB to other patients or to healthcare providers.

Basic Principles

Surveillance

There are several components to a dialysis surveillance program:

- 1) Routinely test and document status of all chronic dialysis patients for HBV and HCV before admission or transfer to dialysis program. Routine testing for hepatitis D virus or HIV is not required.
- 2) Documentation of dialysis patient's vaccination status for vaccine-preventable illnesses.
- 3) On-going regular and documented surveillance for bacteraemia (microorganisms, treatment, date of onset, precautions used, and date resolved), access site infections, and peritonitis.
- 4) Records of each patient's treatment should include documentation of the location of each treatment station used and machine number, as well as names of staff connecting and disconnecting the patient. This information will be useful in any outbreak investigation.

Infection prevention and control measures

- 1) Access site and bloodstream infection prevention
 - Proper hand hygiene must be carried out by all care providers following each of the World Health Organization's (WHO) 5 moments.¹¹
 - Staff must wear a mask and gloves and the patient must wear a mask while the site is being accessed.
 - Locate, inspect, and palpate the access site prior to skin preparation. Repeat skin preparation if the skin is touched by the patient or staff after it has been applied, if cannulation is not completed.
 - For insertion use maximal barrier precautions.
 - Use an alcohol-based chlorhexidine solution (>0.5%) as the skin antiseptic agent for central line insertion, site access, and during dressing changes. Povidone-iodine (preferably with alcohol) or 70% alcohol are alternatives for patients with chlorhexidine intolerance.¹²
 - Scrub catheter hubs with a manufacturer-approved antiseptic after cap is removed and before accessing. Perform every time catheter is accessed or disconnected.¹²
 - Apply antibiotic ointment or povidone-iodine ointment to catheter exit sites during dressing change.¹²
 - Access lines used for HD must not be used for other purposes.⁹
 - Femoral insertion site should be avoided due to increased risk of infection at this site.
- 2) Standard and transmission-based precautions
 - All staff must use Standard Precautions, including hand hygiene, for dialysis patients.
 - Staff must follow established procedures for Contact Precautions for antibiotic-resistant microorganisms, such as MRSA and VRE, other relevant antibiotic-resistant Gram-negative microbes and *C. difficile*.
 - Items taken to a patient's dialysis station, including those placed on top of the dialysis machine, should either be disposed of, dedicated for use only on a single patient, or cleaned and disinfected before being returned to a common clean area or used for other patients. Unused medications or supplies (e.g., syringes, alcohol swabs) taken to the patient's station should not be returned to a common clean area or used on other patients.⁵
 - Staff should ensure segregation of HBsAg-positive patients and their equipment and supplies

from those used for non-HBV-infected patients. Staff members caring for HBsAg-antigen positive patients should not care for HBV susceptible patients at the same time. Segregation of HBsAg-positive patients and their equipment can result in substantial reduction in the incidence of HBV transmission and infection amongst HD patients.⁵

- Isolation of patients with HCV and HIV infection is not necessary or recommended.

3) Environmental cleaning and disinfection

- Adequate environmental cleaning with a hospital grade disinfectant is required after each patient, for all patient areas. Pay special attention to high-touch items or surfaces likely to be contaminated with blood or body fluids.
- There should be procedures to ensure prompt containment and cleaning of spills of blood or body fluids.
- There should also be procedures to ensure prevention of mould contamination resulting from water damage or wetting of permeable walls, furniture, or other items.
- Used supplies and dialysers should be disposed of to prevent contamination of patients and environmental surfaces.

4) Equipment cleaning and disinfection

- Regularly maintained, cleaned, and disinfected dialysis equipment and machines, as well as reusable medical supplies, are essential for reducing the risk of infection.
- There must be policies and procedures for, as well as correct care and maintenance of, dialysis systems, including the water treatment system, distribution system, and dialysis machines.
- Manufacturer recommendations for equipment must be followed.¹⁰
- Reusable dialysers must be cleaned, receive high-level disinfection, and be thoroughly rinsed and dried prior to reuse. They must be stored to prevent contamination.⁸
- There must be adequate cleaning and disinfection of dialysis machines and equipment and reusable supplies between all patient uses.

5) Safe medication and injection practices

- Single-use vials are preferable whenever possible. Medications packaged as multi-dose vials should be assigned to a single patient whenever possible.¹³
- If necessary to use multi-dose vials, steps must be taken to avoid contamination of the vial. The stopper should be disinfected with alcohol before accessing the vial. A single-use sterile needle and syringe should be used for each access.
- Needles should not be recapped.
- All used sharps should be discarded in designated sharps containers.
- Sharps containers should be available at the point of care to avoid carrying used needles.
- Safety engineered medical devices (e.g., self-retracting or self-sheathing needles) should be used when possible.

6) Patient immunisation, post-vaccination testing, and screening

- Screening programs for HBV and HCV are essential.⁵
- All dialysis patients must be screened for HBV prior to start of HD treatment.
- Immunise for HBV. Testing for HBV should take place one to two months after the primary vaccinations are complete. The need for a booster dose of hepatitis B vaccine should be assessed

through annual testing for antibody to HBsAg (anti-HBs). A booster dose should be administered when anti-HBs levels decline to <10 mIU/ml. Higher doses or increased number of doses of hepatitis B vaccine are recommended for dialysis patients. There are other formulations of hepatitis B vaccine designed specifically for haemodialysis patients and other immunocompromised patients which contains an increased dosage and more frequent administration.⁶

- HBV susceptible including vaccine non-responders must be screened for HBsAg monthly⁴⁻⁵
- Patients should be screened for HCV prior to receiving HD⁴⁻⁵ and at 6-month intervals.
- Dialysis patients younger than 65 years of age should receive a dose of pneumococcal vaccine followed by a dose every 5 years. If over 65 years, two doses of vaccine may be required as outlined in national or regional guidelines.
- Screening of patients for MRSA or VRE is only necessary when there is an outbreak or suspected transmission on the dialysis unit.

7) Patient and healthcare provider education

- The staff should receive initial and on-going education on the basic principles and practices of dialysis, infectious risks and potential adverse events, and IPC practices.
- The patient should receive education on hand hygiene, access site and dressing care, signs and symptoms of infection, and the importance of reporting potential infections.
- Patient should also receive education about basic IPC practices during the cannulation process as a means to engage patients.

8) Occupational safety considerations

- Staff who care for dialysis patients must follow Standard Precautions and, as necessary, transmission-based precautions, including use of appropriate personal protective equipment and hand hygiene to protect themselves from contact with and potential infection from blood or body fluids.
- Clean gloves, masks, and gowns must be used when connecting and disconnecting dialysis patients during the dialysis process.
- Routine testing of staff for HCV, HBV, or MDRO is not recommended.
- Staff should receive hepatitis B vaccination.

9) Water treatment and testing

- Water treatment facilities and equipment should be considered patient care equipment. The clinician in charge of dialysis should be involved in planning, design, and installation or revision of the dialysis water treatment facility and equipment.⁹
- Testing of dialysis water and dialysate should be performed as per the USA's Association for the Advancement of Medical Instrumentation (AAMI) guidelines⁸ or British Standards Institution (BSI) guidelines.⁹
- Testing of dialysis water for chlorine should be performed at least weekly, for total viable counts. Test for endotoxin at least monthly and for other chemical contaminants at least every 3 months.⁹
- Water used to prepare dialysate or to process dialysers and dialysate should contain a total viable microbial count of no more than 100 CFU/ml and an endotoxin concentration lower than 0.25 EU/ml for dialysis water and 0.5 EU/ml for dialysate. Wherever possible utilize facilities that are capable of the production of dialysis water with concentrations of microbiological contaminants and endotoxin < 0.1 CFU/mL and < 0.03EU/mL respectively.⁹
- If routine monitoring of dialysis water shows microbiological contaminant levels in excess of 50% of the maximum permitted levels, corrective measures should be instituted immediately.⁹

- There should also be procedures and policies for testing and for follow-up when results are not within acceptable limits.

Low Resource Issues

In areas where access to resources is limited, the main IPC priorities are:

- 1) Safe reprocessing and reuse of dialysers.
- 2) Use, maintenance, and testing of safe, reliable water supply for dialysis.¹⁴
- 3) Spatial separation or segregation of patients infected with HBV or infected or colonised with MDRO, such as MRSA and VRE. Supplies should also be kept separate.
- 4) Access to reliable methods for regular cleaning and disinfection of surfaces and equipment in the dialysis area.
- 5) Access to lab testing for HBV/HCV status of patients and detection of other infections related to dialysis.
- 6) Access to HBV vaccine for patients and staff.
- 7) Proper hand hygiene following each of the WHO's 5 moments.

Relevant Guidelines

1. Kidney Disease Outcomes Quality Initiative (KDOQI). <http://www.kidney.org/professionals/KDOQI/guidelines.cfm> [Accessed 18 September 2015]
2. Peritoneal dialysis-related infections recommendations: 2010 update. <http://www.pdiconnect.com/content/30/4/393.full.pdf+html> [Accessed 18 September 2015]
3. International Society for Peritoneal Dialysis (ISPD) Position Statement on Reducing the Risks of Peritoneal Dialysis-related infections 2011. *Perit Dialysis Int* 2011; 31: 614-630. <http://www.pdiconnect.com/content/31/6/614.full.pdf+html> [Accessed 18 September 2015]
4. Centre for Healthcare Related Infection Surveillance and Prevention and Tuberculosis Control. Prevention and Control of infections in Dialysis Settings, 2013. http://www.health.qld.gov.au/chrsp/policy_framework/renal_guideline.pdf [Accessed 18 September 2015]
5. Medical Development Division. Ministry of Health. Malaysia Haemodialysis Quality and Standards, 2012. http://www.moh.gov.my/images/gallery/Garispanduan/Haemodialysis_Quality_Standards.pdf [Accessed 18 September 2015]
6. Canadian Association of Nephrology Nurses and Technologists. Nephrology Nursing Standards and Practice Recommendations, 2008. http://www.cannt.ca/files/CANNT_Nursing_Standards_2008.pdf [Accessed 18 September 2015]

Summary

Dialysis (HD or PD) is a lifeline for patients with ESRD or renal failure and/or awaiting kidney transplant, however patients receiving dialysis treatments are at increased risk of infection. The risk of infection or other adverse events can be reduced by prevention and control measures. Implementation of IPC procedures and a safe environment, including safe water, are all critical in eliminating or mitigating infection risk for this group of patients. The patient also has an important part to play in preventing infection and requires appropriate education.

References

1. Ronco C, Aquila R, Rodighiero MP (eds): Peritoneal Dialysis: A Clinical Update. *Contrib Nephrol Basel* 2006; 150: 181-186.
2. National Kidney and Urologic Diseases Information Clearinghouse. National Institute of Diabetes and

- Digestive and Kidney Diseases (NIDDK). <http://kidney.niddk.nih.gov/> [Accessed 18 September 2015]
3. Kam-Tao Li, P, Szeto, C Piraino, B. et al. ISPD guidelines/recommendations: Peritoneal dialysis-related infections recommendations: 2010 update. *Perit Dialysis Int* July/August 2010; 30: 393-423.
 4. Alter M, et al. Nosocomial infections associated with hemodialysis. In: CG Mayhall (ed), *Hospital Epidemiology and Infection Control*, 4th edition, Lippincott Williams and Wilkins, Baltimore, MD, 2011; 1139-72.
 5. CDC Recommendations for Preventing Transmission of Infections among Chronic Hemodialysis Patients. *MMWR* 2001; 50(RR05):1-43. <http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5005a1.htm> [Accessed 18 September 2015]
 6. Advisory Committee on Immunization Practices (ACIP). Guidelines for Vaccinating Dialysis Patients and Patients with Chronic Kidney Disease, December 2014. <http://www.cdc.gov/vaccines/pubs/downloads/dialysis-guide-2012.pdf> [Accessed 18 September 2015]
 7. Grota P, Allen V, Boston KM, et al, eds. In *APIC Text of Infection Control & Epidemiology*. 4th Edition. Washington, D.C.: Association for Professionals in Infection Control and Epidemiology, Inc.; 2014.;39.
 8. AAMI Standards and Recommended Practices for Dialysis. Arlington VA. Association for the Advancement of Medical Instrumentation, 2010.
 9. *BSI Concentrates for haemodialysis and related therapies*. British Standards Institute. BS EN 13867:2002+A1:2009.
 10. Friedman C, Petersen K. *Infection control in ambulatory care*. Jones and Bartlett, Sudbury, Massachusetts; 2004; 97-108.
 11. World Health Organization Guidelines on Hand Hygiene in Health Care, 2009. <http://apps.who.int/medicinedocs/documents/s16320e/s16320e.pdf> [Accessed 18 September 2015]
 12. Infection Control Requirements for Dialysis Facilities and Clarification Regarding Guidance on Parenteral Medication Vials, 2008. <http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5732a3.htm> [Accessed 18 September 2015]
 13. CDC Approach to BSI Prevention in Dialysis Facilities (i.e., the Core Interventions for Dialysis Bloodstream Infection (BSI) Prevention), 2014. <http://www.cdc.gov/dialysis/prevention-tools/core-interventions.html> [Accessed 18 September 2015]
 14. Vivekanand J. ESRD in South Asia. *Ethnicity & Dis* 2009;19: S1-27-S1-32. <http://www.ishib.org/journal/19-1s1/ethn-19-01s1-27.pdf> [Accessed 18 September 2015]

While the advice and information in this chapter is believed to be true and accurate, neither the authors nor the International Federation of Infection Control can accept any legal responsibility or liability for any loss or damage arising from actions or decisions based on this chapter.

Published by the International Federation Of Infection Control
47 Wentworth Green
Portadown, BT62 3WG, N Ireland, UK
www.theifc.org

©International Federation of Infection Control, 2016. All rights reserved.